CCO Independent Conference Coverage: Clinical Impact of New HIV Data From Fall 2022 Conferences*

Download All
Washington, DC - October 19-23, 2022; Glasgow, Scotland and virtual - October 23-26, 2022
Engage in this scientific analysis of data presented at IDWeek and HIV Glasgow 2022, with rapid postconference webinars by expert faculty and Capsule Summaries on key HIV prevention and treatment studies and new and investigational ART regimens. Watch the on-demand webinars, download the slides, and gain global perspectives with companion ClinicalThought commentaries.
José R. Arribas, MD
Brenda E. Crabtree Ramírez, MD
Joseph J. Eron, Jr., MD
person default
Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB
Milosz Parczewski, MD, PhD
Don Smith, MD
Babafemi Taiwo, MBBS
Darrell H. S. Tan, MD, FRCPC, PhD
person default
Yan Zhao, MD


The FDA placed a clinical hold on the islatravir development program in late 2021, but new data reported at HIV Glasgow 2022 identify an optimized dose that permits resumed clinical development of this investigational reverse-transcriptase translocation inhibitor. Here are my thoughts on what we learned.

Babafemi Taiwo, MBBS Released: November 17, 2022

As the use of 2-drug antiretroviral therapy regimens for HIV treatment continues to increase, so does the importance of ensuring that our patients have adequate HBV immunity. This highlights the significance of an IDWeek 2022 presentation evaluating the recently approved HepB-CpG vaccine in people with HIV.

Joseph J. Eron, Jr., MD Released: November 22, 2022

In Central and Eastern Europe, the Russian invasion of Ukraine is affecting HIV care, with an impact being seen on PrEP implementation in Ukraine and HIV treatment for refugees in Poland.

Milosz Parczewski, MD, PhD Released: November 22, 2022

As this new option starts to become available in Spain, I take a look at how new data presented at HIV Glasgow 2022 will affect my clinical practice.

José R. Arribas, MD Released: November 21, 2022

In expanded multivariable analyses from ATLAS, ATLAS-2M, and FLAIR of people with HIV receiving long-acting cabotegravir plus rilpivirine, factors most predictive of confirmed virologic failure were preexisting rilpivirine resistance-associated mutations and HIV-1 subtype A6/A1.

Darrell H. S. Tan, MD, FRCPC, PhD Released: November 22, 2022

Do the results with long-acting ART in real-world settings match what we saw in clinical trials? Here are my thoughts on the latest data from the fall 2022 HIV conferences.

Don Smith, MD Released: November 22, 2022

A modeling analysis of islatravir doses predicted that at 0.25 mg daily, lymphocyte changes would be similar to other ART regimens and effective concentrations would be reached. In the real-world US OPERA Cohort, long-acting cabotegravir plus rilpivirine was highly effective.

Brenda E. Crabtree Ramírez, MD Released: November 22, 2022

At IDWeek 2022, investigators reported new findings from a long-term analysis of the randomized START trial comparing immediate vs delayed ART initiation. The results continue to reinforce the benefits of early vs later ART start and also support strategies in China that have successfully decreased time to ART initiation among newly diagnosed individuals.

person default Yan Zhao, MD Released: November 22, 2022

To me, the most important analysis presented at the fall conferences for HIV healthcare professionals in Sub-Saharan Africa was a plenary presentation addressing progress and challenges related to identifying and treating cryptococcal meningitis in PWH .

person default Sylvia Ojoo, CCST (UK), MRCP (UK), DTM&H (UK), DFFP (UK), MBChB Released: December 6, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings